Health Condition 1: F339- Major depressive disorder, recurrent, unspecified
Conditions
Interventions
Intervention1: Lumateperone or Placebo: Details:
Route: Oral
Dose: Formulated Capsules (42 mg)
Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or
Sponsors
Intra-Cellular Therapies, Inc.
IQVIA RDSIndia Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Provides written informed consent 2. Male or female patients between the ages 18 and 65 years, inclusive 3. Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT), and meet all the following criteria: a. The start of the current MDE is at least 12 weeks but no more than 18 months prior to Screening (Visit 1) b. Has at least moderate severity of illness based on rater administered MADRS total score >= 24 at Screening (Visit 1) and at Baseline (Visit 2) c. Has at least moderate severity of illness based on CGI-S score >= 4 at Screening (Visit 1) and at Baseline (Visit 2) d. Has a QIDS-SR-16 score >= 14 at Screening (Visit 1) and at Baseline (Visit 2) e. Has sufficient history and medical record confirmation (as defined in the Study Reference Manual) verifying ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning. 4. Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the ATRQ and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration and: a. citalopram/escitalopram b. fluoxetine c. paroxetine d. sertraline e. duloxetine f. levomilnacipran/milnacipran (if locally approved for MDD) g. venlafaxine/desvenlafaxine h. bupropion i. vilazodone j. vortioxetine
Exclusion criteria
Exclusion criteria: 1. Within the patientâ??s lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including: a. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder b. Bipolar disorder 2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including: a. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment b. Eating disorder c. Substance use disorders (excluding nicotine) d. Personality disorder of sufficient severity to have a major impact on the patientâ??s psychiatric status; e. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment; 3. The patient experiences a >= 25% decrease in the MADRS total score between Screening (Visit 1) and Baseline (Visit 2) 4. The patient experiences a >= 25% decrease in the QIDS-SR-16 total score between Screening (Visit 1) and Baseline (Visit 2) 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or: a. At Screening (Visit 1), the patient scores â??yes ? on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline (Visit 2), the patient scores â??yes ? on Suicidal Ideation Items 4 or 5 since the Screening Visit b. At Screening (Visit 1), the patient has had 1 or more suicide attempts within 2 years prior to Screening c. At Screening (Visit 1) or Baseline (Visit 2), the patient scores >= 5 on MADRS Item 10 (Suicidal Thoughts), or d. The patient is considered to be in imminent danger to him/herself or others. 6. The patient has a first MDE at age 60 years or older.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing antidepressant therapy (ADT) as measured by change from baseline to Day 43 in the Montgomery-Ã?sberg Depression Rating Scale (MADRS) total scoreTimepoint: Day 43 | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to ADT in patients with MDD who have an inadequate response to ongoing ADT as measured by change from baseline to Day 43 in the Clinical Global Impression Scale-Severity (CGI-S)Timepoint: Day 43 | — |
Countries
Bulgaria, France, India, Lithuania, Serbia, Spain, United States of America
Contacts
Public ContactShweta Pradhan
IQVIA RDS (India) Private Limited
Outcome results
None listed